The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice
Aging Cell · 2024
DOI: 10.1111/acel.14272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2024. Verfasst von Inés Muela-Zarzuela und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, Seville, Spain. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Pyridines, Progeria, Furans. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Progeria Research Foundation.
Abstract (Originalsprache)
The role of the inflammasomes in aging and progeroid syndromes remain understudied. Recently, MCC950, a NLRP3 inhibitor, was used in Zmpste24 −/− mice to ameliorate the phenotypes. However, the safety of MCC950 was questioned due to liver toxicity observed in humans. Nevertheless, inhibition of the inflammasomes would be a beneficial therapy for progeria. Here, we show that OLT1177 (dapansutrile), other NLRP3 inhibitor, improved cellular and animal phenotypes using progeroid fibroblasts and a Lmna G609G/G609G mouse model. In both cases dapansutrile reduced progerin accumulation, NLRP3‐inflammasome activation and secretory phenotype of senescence, extended the lifespan of progeroid animals, preserved bodyweight, and reduced kyphosis, inflammation, and senescence. Interestingly, dapansutrile further improved the effect of lonafarnib, the only FDA‐approved drug for the progeria. The combination of both drugs reduced the inflammation and senescence, extended survival and ameliorated various progeroid defects both in vitro and in vivo, compared with treatment using lonafarnib alone. These findings and the safety of dapansutrile demonstrated in several clinical trials proposes it as a possible co‐adjuvant treatment with lonafarnid in HGPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, Seville, Spain.
- Department of Immunology, Puerta del Mar Hospital, Cádiz, Spain.
- Instituto de Investigación e Innovación Biomédica de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain.
- Departamento de Química Orgánica, Facultad de Ciencias, Campus Universitario Río San Pedro s/n, Torre Sur, 4a Planta, University of Cádiz, Cádiz, Spain.
- School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
ORCID-Profile: Mario D Cordero
Förderung
- Progeria Research Foundation
Zitieren
APA
Muela-Zarzuela, I., Suarez-Rivero, J. M., Boy-Ruiz, D., López-Pérez, J., Sotelo-Montoro, M., Del Mar Navarrete-Alonso, M., Collado, I. G., Botubol-Ares, J. M., Sanz, A., & Cordero, M. D. (2024). The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice. Aging Cell. https://doi.org/10.1111/acel.14272
Vancouver
Muela-Zarzuela I, Suarez-Rivero JM, Boy-Ruiz D, López-Pérez J, Sotelo-Montoro M, Del Mar Navarrete-Alonso M, et al. The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice. Aging Cell. 2024. doi:10.1111/acel.14272
BibTeX
@article{MuelaZarzuela2024,
author = {Muela-Zarzuela, Inés and Suarez-Rivero, Juan Miguel and Boy-Ruiz, Daniel and López-Pérez, Juan and Sotelo-Montoro, Marta and Del Mar Navarrete-Alonso, Maria and Collado, Isidro G and Botubol-Ares, José Manuel and Sanz, Alberto and Cordero, Mario D},
title = {The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice},
journal = {Aging Cell},
year = {2024},
doi = {10.1111/acel.14272}
}
EUVIMED